Similar Items: Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer with PD-L1-positive: a cost-effectiveness analysis
- Reducing breast cancer recurrences with CDK4/6 inhibitor treatment of HR-positive, HER2-negative early stage breast cancer from a societal perspective
- Pooled survival and cost-effectiveness analysis of immune checkpoint inhibitors-based for metastatic non-small-cell lung cancer with PD-L1 lower than 1%
- Spatial characterization of the BT-20 triple negative breast cancer spheroidal model
- A Case of Acalculous Cholecystitis During Lenvatinib Plus Pembrolizumab Therapy for Advanced Renal Cell Carcinoma
- Probing the exchange rate’s asymmetric reaction to oil price changes in the new BRICS Plus group
- Do Perceptions of Inequality Negatively Affect Interpersonal Trust?